analogue of mitozolomide. was subsequently selected for clinical development because of its demonstrated anti-tumour activitv and more favourable toxicity profile in preclinical testing (Stevens et al. 1987) .
Temozolomide undergoes spontaneous degradation at physiological pH to the active moiety. monomethvl triazenoimidazole carboxamide (MTIC: Fiaure 1: Stevens et al. 1987) . The cytotoxicity of MTIC is thought to result from the reactive methylation of guanine.
primarily at the 0( position and to a lesser extent the N-position (Catapano et al. 1987 ). Resistance to temozolomide-mediated cytotoxicity correlates both with the expression of a specific DNA repair protein. 06-methylguanine DNA methyltransferase (MGMT). which removes (iY6-methylguarine adducts byt self-inactivation (Catapano et al. 1987) and the presence of a deficiency in the mismatch repair pathway (Wedge et al. 1996 .
In preclinical testing. temozolomide was found to have scheduledependent anti-tumour activity against a broad spectrum of murine tusmonrs in vivo. including leukaemias. lymphomas and solid tumours (Stevens et al. 1987) . The initial phase I study in adults used a Cancer Research Campaign (CRC) formulation of temozolomide (CCRG 81045: Newlands et al. 1992) . Temozolomide was initially studied with a single-dose schedule and demonstrated linear pharmacokinetics with increasing dose and myelosuppression as the doselimiting toxicity. No anti-tumour activity was seen in the 51 patients studied (Newlands et al. 1992) . However, when temozolomide was given orally over 5 consecutive days. activity was observed in patients with high-grade astrocytomas (HGA) . malignant melanoma and in one patient with mycosis fungoides. As in the single-dose schedule. myelosuppression was found to be dose limiting (Newlands et al. 1992) . The recommended phase HI dose was 750 mO M-' for the first treatment cycle. followed by 1000 mg m-' for subsequent cycles if there was no dose-limiting myelosuppression on the first cycle. Phase H studies with the CRC formulation of temozolomide have subsequently shown activity in phase H trials with HGA (O'Reilly et al. 1993 ) and metastatic melanoma (Bleehen et al. 1995) but not with low-grade non-Hodgkin's lymphoma (Woll et al. 1995) .
For clinical development in the USA. a phase I trial of temozolomide (NSC 362856) . which differs from the CRC preparation with regard to inert ingredients. has also demonstrated dose-limiting myelosuppression (Dhodapkar et al. 1997 ). Subsequently. a new formulation of temozolomide. SCH 52365. has been developed by Schering-Plough. SCH 52365 has been re-evaluated in phase I studies in adult patients. confirming similar toxicity findings and maximum-tolerated dose for this formulation (Brada et al. 1995 . (SCH 52365) total protein. albumin. alanine aminotransferase. alkaline phosphatase were carried out weekly for the first two cycles. Patients were then reviewed at the end of each treatment cycle and the above assessments repeated. Radiological evaluation of tumour sites was performed at the end of each of the first two treatment cycles. and then after alternate cycles. Patients were evaluable for response if they received 5 days of temozolomide and were evaluable for toxicity if they survived for at least a further 23 days. Tumour responses were graded according to WHO guidelines (WHO. 1979) . Complete response (CR) was defined as the complete disappearance of all detectable disease. Partial response (PR) was defined as greater than 50% reduction in the sum of the products of the two largest perpendicular diameters of all measurable lesions. Stable disease (SD) was defined as a less than 50% reduction but not greater than 25% increase in the sum of the products of the two largest perpendicular diameters of all measurable lesions. All assessments of response and stable disease were determined by two observations not less than 4 weeks apart.
Progressive disease (PD) was defined as a greater than 25% increase in the sum of the products of the two largest perpendicular diameters of all measurable lesions. or the appearance of any new lesions. Radiological imaging before therapy. after two courses and at time of maximal response was reviewed centrally and independently by two experienced paediatric neuroradiologists. The pathology of all responding patients was reviewed centrally.
Dose escalation
Temozolomide dosage was based on body surface area, which was calculated according to the formula recommended by Mosteller (1987) :
The dose given was the nearest that the capsules allowed. with approximation increasing the dose if necessary. Arm A was escalated through four dose levels: 500. 800. 1000 and 1200 ma m-' per cycle. Arm B was dose escalated from 500 to 600 mg m-2 per cycle before this arm of the trial was closed. Patients were recruited in cohorts of three per dose level. and dose-limiting toxicity was defined from the safety profile of cycle 1 for each patient. No within-patient dose escalations were allowed.
Definition of DLT and MTD
Toxicity was evaluated according to the Common Toxicity Criteria (CTC). A dose-limiting toxicity was defined during the first 28 days after the first daily dose of SCH 52365 as follows:
1. CTC grade 4 neutropenia that did not resolve within 7 days.
grade 4 anaemia or grade 3 thrombocytopenia that did not resolve within 7 days. CTC grade 4 thrombocytopenia of any duration was also taken to be dose limiting.
2. Other CTC grade 3 or 4 toxicity except for grade 3 nausea and vomiting, grade 3 fever (in the absence of infection) and grade 3 hepatic toxicity that returned to a minimum of grade 1 before the commencement of the next treatment cycle.
When DLT was encountered in one patient of a cohort of three. a maximum of three additional patients were treated at that level. If DLT was not observed with the additional patients. then the next dose level was entered. The MTD was defined as that dose level immediately below the dose level at which a minimum of two patients in a cohort of three to six patients experienced DLT. A maximum of one out of six patients could experience DLT at the MTD dose level. A total of six patients were treated at the MTD dose level to fully assess toxicity. This strategy allowed the MTID to be estimated using a minimum number of patients (Kom et al. 1994 ).
Pharmacokinetics
Pharmacokinetic evaluations were performed during cycle 1 for at least two evaluable patients per dose level. Blood samples were required to construct the standard cursve 0.1-20 pj ml-') and at least six or nine quality control (QC) samples (0.2. 1.5. 15 jg ml-) were made up in acidified analyte-free human plasma (120 il of 8.5% (/vlx) phosphoric acid per 4 ml of human plasma). Patient plasma samples were allowed to thaw in a water bath at room temperature. and 0.5-ml aliquots pipetted into separate 16 x 125-mm screw cap glass culture tubes. This was followed bv the addition of 0.5 ml of the IS working solution and all samples were acidified by the addition of 50 il of 1 N hydrochloric acid. Five millilitres of ethvl acetate was then added to each tube. and the contents mixed in a shaker for 10 min. The samples were centrifuged at 3000 g for 5 min. and the organic layer transferred to a separate 16 x 100-mm culture lass tube by freezing the aqueous laver in a drx ice bath. The organic layer was evaporated to drvness at 45 C under air. The residue was then reconstituted in 0.3 ml of mobile phase ( For the plasma and urine SCH 52365 assays. the accuracy. precision and inter/intraday variabilities were < 15%c.
Pharmacokinetic data
The following pharmacokinetic parameters A-ere summarized for each patient: at days 22. 23 and 23 for the three patients with dose-limiting thrombocytopenia. In these three patients. the platelet count recovered to > 100 x 109/1-' by days 29. 32 and 65. The nadir neutrophil count occurred at days 29 and 24 and recovered to > 1 x l09/1-1 by days 43 and 27. Two of the six evaluable patients at the 1000 Mmgm2 per cycle dose level had received prior chemotherapy. and dose-limiting thrombocytopenia was observed in one of these patients (who had received prior vincristine and cisplatin). Two of the four evaluable patients entered at the 1200 mg m-2per cycle dose level had received prior chemotherapy. and doselimiting thrombocytopenia was observed in one of these patients (who had received prior thiotepa). The three patients experiencing dose-limiting myleosuppression during cycle 1 had a 20% reduction in their temozolomide dosage for cycle 2. In addition. one further patient at the 1200 mg m-2 dose level experienced grade 4 neutropenia and grade 4 thrombocytopenia in cycle 2 and continued temozolomide after a dose reduction. Grade 3 anaemia was also observed in those patients experiencing dose-limiting myelosuppression. No haematological toxicity was observed in Arm B. except for one patient who had been misrandomized and who had received the highest dose of Arn A (1200 mg mu2 per cycle). This patient experienced CTC grade 4 thrombocytopenia and neutropenia, and grade 3 anaemia The MTD of temozolomide was therefore defined as 1000 mg m-2 per cycle in patients who had not received prior spinal irradiation or nitrosoureas.
The main non-haematologcal toxicities associated with temozolomide in Arm A were nausea. vomiting, headache, constipation and ataxia (Table 4) . Nausea and vomiting were common but were easily controlled with standard antiemetic therapy. The majority of nonhaematological adverse events were CTC grade 1 or 2 (Table 5 ). Phase I trial of temozolomide (SCH52365) in children 657 patients, and the plasma pharmacokinetic analyses for these patients are shown in Table 5 . Pharmacokinetic profiles for each dose level (both arms combined) are shown in Figure 2 and demonstrate the rapid absorption and elimination of oral temozolomide in this patient population. A significant linear relationship was found between the peak plasma concentration of temozolomide and increasing dose of temozolomide (r' = 0.36. P < 0.01; Figure 3 ). Similarly, a significant linear relationship was found for the AUC (I) and increasing doses of temozolomide (r2 = 0.69. P < 0.0001: Figure 4 ). Interpatient variability for systemic exposure (AUC) to temozolomide was small at each dose level, with a coefficient of variation of less than 20% (Figure 4 and Table 6 ). Temozolomide was undetectable before administration on each of the 5-day courses of treatment. On day 5, maximum plasma temozolomide concentrations were achieved approximately 1.5 h after dosing. and the mean to:1 ranged from 1.4 to 1.9 h. Individual apparent total body clearance (CLEF) ranged from 56.1 to 107 ml min-' m-' and was dose independent, assuming that temozolomide has a bioavailability of 100% in this paediatric population. The individual Vdarea/F ranged from 8.27 to 15.41 m-2. Pharmacokinetic comparisons between the two arms of the study were only possible for the 500 mg m-' per cycle dose level. and similar results for each arm were obtained. Plasma pharmacokinetics were measured in four of the six patients who encountered grade 3 or 4 haematological toxicity. Three patients achieved an AUC of > 50 jg h mlF. and two of these patients experienced dose-limiting thrombocytopenia. However. one patient at the 800 mg m-' per cycle dose level experienced only grade 2 thrombocytopenia with an AUC of 62 lag h ml-'.
Urinary excretion was measured in 13 patients. Urinary recovery of temozolomide ranged from 5% to 15% of the dose administered over the 24-h collection period. Individual renal clearances ranged from 2.7 to 10.7 ml min-' M-2 and was dose independent. Because temozolomide undergoes chemical degradation in the body at physiological pH. the limited renal clearance. compared with the apparent total body clearance (CU/F) was expected.
Efficacy
Three of 15 patients with high-grade astrocytomas and diffuse intrinsic brain stem gliomas responded (one CR and two PR). In addition, three patients had stable disease of 6, 6 and 4 months duration (Table 6 ). One of the ten patients with brain stem glioma had a partial response and was withdrawn from the study in response after 13 cycles of treatment. This patient. a 4-year-old girl with a grade 3 astrocytoma. progressed during radiotherapy (54 Gy). as documented on computerized tomography (CT) scan.
Britsh Joural of Cancer (1998) 78(5) Debulking surgery was required in the 5th week of the 6-week course of radiotherapy. Radiotherapy was completed 24 days before commencing temozolomide, and the radiological response is demonstrated in Figure 5 . After one course of temozolomide. the tumour remained unchanged in size, but showed less enhancement than at baseline. After two courses, the tumour appeared necrotic. with a 12.5% reduction in the product of two maximal perpendicular diameters. A maximum response of a 81% reduction was observed after 32 weeks of therapy. Clinical improvement was noted during the first cycle of therapy and was maintained. allowing the gradual withdrawal of dexamethasone by week 10. The patient received 1 year of therapy in total. In two further patients with diffuse intrinsic brain stem gliomas, stable disease was observed for 20 and 27 weeks. Five patients progressed after two courses, and one patient progressed after one course of therapy. A further patient died on the 14th day of cycle 1 because of disease progression.
Two of five patients with high-grade astrocytoma responded (one complete response and one partial response). An 8-year-old girl with a grade 3 anaplastic astrocytoma progressed after radiotherapy (54 Gy) to an unresected left cerebral hemisphere tumour. A was taken at relapse, B after two courses of SCH 52365 (partal response) and C at the time of maxinal response (at 17 weeks), in a 9-year-old girl with a glooblastoma, which recurred 62 weeks after total excision and radiotherapy two maximal perpendicular diameters of the tumour was observed after two cycles of therapy, and no tumour was detectable after 52 weeks of therapy. During this time. the patient showed continued improvement in her right-sided hemiplegia, and therapy with dexamethasone was withdrawn by week 14. The patient relapsed with disease in the contralateral (non-irradiated) cerebral hemisphere 5 months after temozolomide was discontinued.
Another patient. a 9-year-old girl with a right cerebral giant-cell glioblastoma. had a total resection and radiotherapy (54 Gy) 14 months before her relapse. After two courses of therapy with temozolomide, a 70% reduction in the product of the two maximal perpendicular diameters of the tumour was observed, and the maximum response of a 81% reduction was observed after 16 weeks ( Figure 6 ). This patient became asymptomatic during the course of her therapy with temozolomide. allowing the withdrawal of dexamethasone by week 8. The partial response lasted for 20 weeks. One further patient had stable disease lasting 4 months.
All patients with primitive neuroectodermal tumours (six). ependymoma (one) . rhabdomyosarcoma (one), chondrosarcoma (one). osteogenic sarcoma (one). pancreatic neuroendocrine tumour (one) and haemangiopericytoma (one) progressed after one or two courses of therapy.
DISCUSSION
This phase I study has determined the dose-limiting toxicities. MTD and pharmacokinetics of oral temozolomide in children who have not received prior therapy with CSI or nitrosoureas. Although the MTD of temozolomide given orally for 5 days has been established in adults (Newlands et al. 1992 : Brada et al. 1995 (Marsoni et al, 1985) .
As previous studies in children have shown that the MT) of anti-cancer agents can be influenced by the intensity of prior therapy (Pearson et al, 1994) , patients were initially stratified according to whether or not they had received prior CSI or nitrosourea therapy. However, entry to the prior CSI/nitrosourea arm of the study was closed after the initial two dose levels because of poor recruitment Because, at the beginning of this phase I study, SCH 52365 had not been fully evaluated in an adult phase I trial, the starting dose level for both arms of the trial was 50% of the adult MTD estabfished with the original CRC formulation (Newlands et al, 1992) .
The finding of thrombocytopenia as the dose-limiting toxicity in this study is in keeping with the original adult phase I trial of oral temozolomide, in which myelosuppression was found to be dose limiting. As in the adult phase I study (Newlands et al, 1992) (Newlands et al, 1992 : Schering-Plough Research Institute. 1996 , with rapid absorption, rapid elimination, no accumulation on day 5 and a linear increase in peak plasma concentration and systemic exposure with increasing dose. Overall, the plasma concentrations of temozolomide in paediatric patients were approximately 15-30% higher than those observed at similar dose levels in the adult phase I study of SCH 52365 (Brada et al. 1995; Schering-Plough Research Institute, 1996) . Similarly, systemic exposure (AUC) to temozolomide was higher in paediatric patients, with an increase of approximately 40% compared with adult patients (Schering-Plough Research Institute, 1996) . Moreover, an important characteristic of temozolomide is that the pharmacokinetics are reproducible in this patient population, as demonstrated by the small interpatient variability in systemic exposure. Other pharmacokinetic parameters in this pediatric study, i.e. T and tr,. were similar to those observed in adults. As in the adult phase I study of SCH 52365, the urinary clearance of temozolomide was small compared with apparent total body clearance. However, urinary excretion may have been underestiatd 1because of the breakdown of temozolomide in the urine, before micturition and subsequent stabilization of temozolomide by acidification of the urine.
In an adult phase II study of temozolomide in primary brain tuinours (O'Reilly et al, 1993) , major clinical improvement was found in six out of ten evaluable patients with high-grade astrocytomas who had relapsed after radiotherapy. This was accompanied by a marked improvement in radiological appearance in five out of ten patients. Moreover, reduction in the size of tumours was also seen in four out of seven patients with unirradiated astrocytomas (O'Reilly et al, 1993) , confirming the suggestion of activity against HGA observed in the original phase I study (Newlands et al, 1992) . Activity in this paediatric study has been demonstrated in patients with high-grade astrocytoma and brain stem glioma, with measurable and confirmed responses (CR or PR) found in two out of five cases of high-grade astrocytoma, and one out of ten cases of diffuse intrinsic brain stem glioma. Although temozolomide was commenced 24 days after the completion of radiotherapy for the responding patient with a brain stem glioma, it was felt that the clinical and radiological responses seen were attributable to therapy with this agent Response assessment in patients with CNS tumours is known to be difficult; however, only neuroradiological responses were considered in this study. All tumour sizes were measured independently by the local and two central radiologists to ensure a non-biased conclusion. Maximal responses were seen after more than two cycles of therapy in these three patients, in whom the greatest response occurred at 16, 32 and 52 weeks. Two patients with stable disease after two courses subsequently achieved a CR and a PR.
The cytotoxicity of temozolomide is thought to relate primarily to methylation of guanine at the 06 position, and this DNA lesion is repaired by the protein 06-alkylguanine DNA alkyltransferase (Catapano et al, 1987) . The finding that this repair protein cannot be detected in 22% of primary brain tumours (Citron et al, 1991) and that the levels of MGMT in human tumour cells correlate with temozolomide cytotoxicity (Wedge et al, 1996) may prove to be clinically important observations. Indeed, rapid and sustained depletion of MGMT occurs in adult patients with a 200 mg m-2 bolus dose of temozolomide followed by a twice-daily oral regimen for 5 days .
As the prognosis for both high-grade astrocytoma and brain stem glioma in children is poor with current therapy, phase H evaluation of temozolomide is warranted for both of these conditions. Consideration should also be given to evaluating activity of temozolomide in other poor-risk tumours, such as neuroblastoma. in which dacarbazine is known to be active.
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